Deze Zhao

754 total citations
22 papers, 475 citations indexed

About

Deze Zhao is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Deze Zhao has authored 22 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Deze Zhao's work include Cancer Immunotherapy and Biomarkers (7 papers), RNA modifications and cancer (6 papers) and Cancer-related molecular mechanisms research (5 papers). Deze Zhao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), RNA modifications and cancer (6 papers) and Cancer-related molecular mechanisms research (5 papers). Deze Zhao collaborates with scholars based in China and United States. Deze Zhao's co-authors include Xiaochun Zhang, Li Wang, Man Jiang, Kang Qin, Helei Hou, Xiaochun Zhang, Jialin Qu, Chunfang Zhang, Chaojun Duan and Xianyu Liu and has published in prestigious journals such as Scientific Reports, Molecular Cancer and Cell Death and Disease.

In The Last Decade

Deze Zhao

22 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deze Zhao China	14	234	152	130	128	65	22	475
Jinfang Zheng China	12	213 0.9×	107 0.7×	98 0.8×	150 1.2×	60 0.9×	28	398
Yin Cheng China	12	222 0.9×	88 0.6×	159 1.2×	146 1.1×	59 0.9×	37	464
Tianli Cheng China	12	194 0.8×	109 0.7×	150 1.2×	138 1.1×	89 1.4×	25	493
Yu Peng China	14	286 1.2×	86 0.6×	85 0.7×	191 1.5×	29 0.4×	39	460
Alexandru Tirpe Romania	8	214 0.9×	67 0.4×	81 0.6×	203 1.6×	52 0.8×	13	461
Bo Ni China	12	282 1.2×	116 0.8×	128 1.0×	218 1.7×	163 2.5×	30	560
Min Peng China	14	213 0.9×	137 0.9×	206 1.6×	136 1.1×	72 1.1×	60	521
Hiroki Izumi Japan	14	175 0.7×	179 1.2×	251 1.9×	55 0.4×	59 0.9×	68	528
Sisi Liu China	12	147 0.6×	78 0.5×	148 1.1×	52 0.4×	55 0.8×	36	365

Countries citing papers authored by Deze Zhao

Since Specialization

Citations

This map shows the geographic impact of Deze Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deze Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deze Zhao more than expected).

Fields of papers citing papers by Deze Zhao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deze Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deze Zhao. The network helps show where Deze Zhao may publish in the future.

Co-authorship network of co-authors of Deze Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Deze Zhao. A scholar is included among the top collaborators of Deze Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deze Zhao. Deze Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Jiayuan, Yating Dian, Deze Zhao, et al.. (2025). Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. Molecular Cancer. 24(1). 221–221. 9 indexed citations

Guo, Ziyu, Lei Yao, Yuming Sun, et al.. (2025). Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer. Redox Biology. 84. 103686–103686. 8 indexed citations

Zhao, Deze, et al.. (2023). tRNA Modifications and Modifying Enzymes in Disease, the Potential Therapeutic Targets. International Journal of Biological Sciences. 19(4). 1146–1162. 25 indexed citations

Zhao, Deze, Yeping Dong, Dan He, et al.. (2023). Circadian gene ARNTL initiates circGUCY1A2 transcription to suppress non-small cell lung cancer progression via miR-200c-3p/PTEN signaling. Journal of Experimental & Clinical Cancer Research. 42(1). 229–229. 12 indexed citations

Zhao, Deze, Yu Meng, Yating Dian, et al.. (2023). Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy. Redox Biology. 68. 102966–102966. 31 indexed citations

Wang, Youpeng, Mao Zhang, Haoran Li, et al.. (2022). SOCS5 knockdown suppresses metastasis of hepatocellular carcinoma by ameliorating HIF-1α-dependent mitochondrial damage. Cell Death and Disease. 13(11). 918–918. 6 indexed citations

Liu, Xianyu, Deze Zhao, Qun Xie, et al.. (2022). Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients. Scientific Reports. 12(1). 20737–20737. 2 indexed citations

Zhao, Deze, Xianyu Liu, Jiajia Li, et al.. (2022). Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma. Computational and Structural Biotechnology Journal. 20. 5001–5013. 12 indexed citations

Li, Xizhe, Xianyu Liu, Deze Zhao, et al.. (2021). tRNA-derived small RNAs: novel regulators of cancer hallmarks and targets of clinical application. Cell Death Discovery. 7(1). 249–249. 36 indexed citations

10.

Zhao, Deze, Mao Zhang, Chuan Hu, et al.. (2021). Alternative Splicing-Based Differences Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Genes, Immune Microenvironment, and Survival Prognosis. Frontiers in Oncology. 11. 731993–731993. 7 indexed citations

11.

Shi, Wenwen, Bo Dou, Jun Wang, et al.. (2021). XBP1- IGFBP3 Signaling Pathway Promotes NSCLC Invasion and Metastasis. Frontiers in Oncology. 11. 654995–654995. 21 indexed citations

12.

Lin, Changwei, et al.. (2020). Systematic Analyses of the Differentially Expressed Alternative Splicing Events in Gastric Cancer and Its Clinical Significance. Frontiers in Genetics. 11. 522831–522831. 2 indexed citations

13.

Wang, Yun, Man Jiang, Jingjuan Zhu, et al.. (2020). The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 132. 110797–110797. 43 indexed citations

14.

Zhao, Deze, Man Jiang, Xiaochun Zhang, & Helei Hou. (2020). The role of RICTOR amplification in targeted therapy and drug resistance. Molecular Medicine. 26(1). 20–20. 20 indexed citations

15.

Qu, Jialin, Li Wang, Man Jiang, et al.. (2020). <p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p>. Cancer Management and Research. Volume 12. 6493–6509. 27 indexed citations

16.

Qu, Jialin, Man Jiang, Li Wang, et al.. (2020). Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomedicine & Pharmacotherapy. 127. 109996–109996. 35 indexed citations

17.

Tao, Shu, Zhen Zhao, Xin‐Yuan Guan, et al.. (2020). The role of macrophages during breast cancer development and response to chemotherapy. Clinical & Translational Oncology. 22(11). 1938–1951. 26 indexed citations

18.

Wang, Li, Deze Zhao, Kang Qin, Faisal Rehman, & Xiaochun Zhang. (2019). Effect and biomarker of Nivolumab for non–small-cell lung cancer. Biomedicine & Pharmacotherapy. 117. 109199–109199. 25 indexed citations

19.

Zhao, Deze, et al.. (2019). Grey matter changes in patients with vestibular migraine. Clinical Radiology. 74(11). 898.e1–898.e5. 24 indexed citations

20.

Zhao, Deze, Helei Hou, & Xiaochun Zhang. (2018). Progress in the treatment of solid tumors with apatinib: a systematic review. OncoTargets and Therapy. Volume 11. 4137–4147. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact